Complex MLL rearrangements in t(4;11) leukemia patients with absent AF4̇MLL fusion allele

Leukemia

Volumn 21, Issue 6, 2007, Pages 1232-1238

  Kowarz, E ^a   Burmeister, T ^b   Lo Nigro, L ^c   Jansen, M W J C ^d   Delabesse, E ^e   Klingebiel, T ^a   Dingermann, Theo ^a   Meyer, C ^a   Marschalek, R ^a  

^a GOETHE UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF CATANIA   (Italy)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ELONGATION FACTOR 2; GENOMIC DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; ONCOPROTEIN; PROTEIN AF4; TRANSCRIPTION FACTOR PBX1; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ACUTE LEUKEMIA; ARTICLE; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; FUSION GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE REARRANGEMENT; GENETIC RECOMBINATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA CELL; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECIPROCAL CHROMOSOME TRANSLOCATION;

EID: 34249651279     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404686     Document Type: Article

References (52)

1. Felix CA, Hosler MR, Winick NJ, Masterson M, Wilson AE, Lange BJ. ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children. Blood 1995; 85: 3250-3256.
2. Mitterbauer-Hohendanner G, Mannhalter C. The biological and clinical significance of MLL abnormalities in haematological malignancies. Eur J Clin Invest 2004; 34 (Suppl 2): 12-24.
3. Rowley JD. The der(11) chromosome contains the critical breakpoint junction in the 4;11, 9;11, and 11;19 translocations in acute leukemia. Genes Chrom Cancer 1992; 5: 264-266.
4. Meyer C, Schneider B, Jakob S, Strehl S, Attarbaschi A, Schnittger S et al. The MLL recombinome of acute leukemias. Leukemia 2006a; 20: 777-784.
5. Meyer C, Kowarz E, Oehm C, Klingebiel T, Dingermann T, Marschalek R. Genomic DNA of leukemia patients: Target for clinical diagnosis of MLL rearrangements. Biotechnol J 2006b; 1: 656-663.
6. Ayton PM, Cleary ML. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 2001; 20: 5695-5707.
7. Hess JL. Mechanisms of transformation by MLL. Crit Rev Eukaryot Gene Expr 2004; 14: 235-254.
8. Horton SJ, Grier DG, McGonigle GJ, Thompson A, Morrow M, De Silva I et al. Continuous MLL-ENL expression is necessary to establish a 'Hox Code' and maintain immortalization of hematopoietic progenitor cells. Cancer Res 2005; 65: 9245-9252.
9. Rozovskaia T, Feinstein E, Mor O, Foa R, Blechman J, Nakamura T et al. Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4;11) abnormality. Oncogene 2001; 20: 874-878.
10. Ayton PM, Cleary ML. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev 2003; 17: 2298-2307.
11. Zeisig BB, Milne T, Garcia-Cuellar MP, Schreiner S, Martin ME, Fuchs U et al. Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol Cell Biol 2004; 24: 617-628.
12. Hess JL, Bittner CB, Zeisig DT, Bach C, Fuchs U, Borkhardt A et al. c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells. Blood 2006; 108: 297-304.
13. Xia ZB, Popovic R, Chen J, Theisler C, Stuart T, Santillan DA et al. The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression. Proc Natl Acad Sci USA 2005; 102: 14028-14033.
14. Gaussmann A, Wenger T, Eberle I, Bursen A, Bracharz S, Herr I et al. The combined effects of the two reciprocal t(4;11) fusion proteins, MLL · AF4 and AF4 · MLL, confer resistance to apoptosis, cell cycling capacity and growth transformation. Oncogene 2006, [E pub ahead of print].
15. Milne TA, Hughes CM, Lloyd R, Yang Z, Rozenblatt-Rosen O, Dou Y et al. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc Natl Acad Sci USA 2005a; 102: 749-754.
16. Milne TA, Dou Y, Martin ME, Brock HW, Roeder RG, Hess JL. MLL associates specifically with a subset of transcriptionally active target genes. Proc Natl Acad Sci USA 2005b; 102: 14765-14770.
17. Milne TA, Martin ME, Brock HW, Slany RK, Hess JL. Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications. Cancer Res 2005c; 65: 11367-11374.
18. Corral J, Lavenir I, Impey H, Warren AJ, Forster A, Larson TA et al. An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: A method to create fusion oncogenes. Cell 1996; 85: 853-861.
19. Lavau C, Szilvassy SJ, Slany R, Cleary ML. Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J 1997; 16: 4226-4237.
20. Slany RK, Lavau C, Cleary ML. The oncogenic capacity of HRX-ENL requires the transcriptional transactivation activity of ENL and the DNA binding motifs of HRX. Mol Cell Biol 1998; 18: 122-129.
21. Dobson CL, Warren AJ, Pannell R, Forster A, Lavenir I, Corral J et al. The Mll-AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis. EMBO J 1999; 18: 3564-3574.
22. DiMartino JF, Miller T, Ayton PM, Landewe T, Hess JL, Cleary ML et al. A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL. Blood 2000; 96: 3887-3893.
23. Lavau C, Du C, Thirman M, Zeleznik-Le N. Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia. EMBO J 2000a; 19: 4655-4664.
24. Lavau C, Luo RT; Du C, Thirman MJ. Retrovirus-mediated gene transfer of MLL-ELL transforms primary myeloid progenitors and causes acute myeloid leukemias in mice. Proc Natl Acad Sci USA 2000b; 97: 10984-10989.
25. DiMartino JF, Ayton PM, Chen EH, Naftzger CC, Young BD, Cleary ML. The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10. Blood 2002; 99: 3780-3785.
26. Eguchi M, Eguchi-Ishimae M, Greaves M. The small oligomerization domain of gephyrin converts MLL to an oncogene. Blood 2004; 103: 3876-3882.
27. Liu H, Chen B, Xiong H, Huang QH, Zhang QH, Wang ZG et al. Functional contribution of EEN to leukemogenic transformation by MLL-EEN fusion protein. Oncogene 2004; 23: 3385-3394.
28. So CW, Karsunky H, Wong P, Weissman IL, Cleary ML. Leukemic transformation of hematopoietic progenitors by MLL-GAS7 in the absence of Hoxa7 or Hoxa9. Blood 2004a; 103: 3192-3199.
29. So CW, Cleary ML. Dimerization: A versatile switch for oncogenesis. Blood 2004; 104: 919-922.
30. Wang J, Iwasaki H, Krivtsov A, Febbo PG, Thorner AR, Ernst P et al. Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. EMBO J 2005; 24: 368-381.
31. Strehl S, Borkhardt A, Slany R, Fuchs UE, Konig M, Haas OA. The human LASP1 gene is fused to MLL in an acute myeloid leukemia with t(11;17)(q23;q21). Oncogene 2003; 22: 157-160.
32. Metzler M, Forster A, Pannell R, Arends MJ, Daser A, Lobato MN et al. A conditional model of MLL-AF4 B-cell tumourigenesis using invertor technology. Oncogene 2006; 25: 3093-3103.
33. Chen W, Li Q, Hudson WA, Kumar A, Kirchhof N, Kersey JH. A murine Mll-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy. Blood 2006; 108: 669-677.
34. Bursen A, Moritz S, Gaussmann A, Moritz S, Dingermann T, Marschalek R. Interaction of AF4 wild-type and AF4·MLL fusion protein with SIAH proteins: Indication for t(4;11) pathobiology? Oncogene 2004; 23: 6237-6249.
35. Downing JR, Head DR, Raimondi SC, Carroll AJ, Curcio-Brint AM, Motroni TA et al. The der(11)-encoded MLL/AF-4 fusion transcript is consistently detected in t(4;11)(q21;q23)-containing acute lymphoblastic leukemia. Blood 1994; 83: 330-335.
36. Reichel M, Gillert E, Angermuller S, Hensel JP, Heidel F, Lode M et al. Biased distribution of chromosomal breakpoints involving the MLL gene in infants versus children and adults with t(4;11) ALL. Oncogene 2001; 20: 2900-2907.
37. Scharf S, Zech J, Bursen A, Schraets D, Oliver PL, Kliem S et al. Transcription linked to recombination: A gene-internal promoter coincides with the recombination hot spot II of the human MLL gene. Oncogene 2007; 26: 1361-1371.
38. Meyer C, Schneider B, Reichel M, Angermueller S, Strehl S, Schnittger S et al. Diagnostic tool for the identification of MLL rearrangements including unknown partner genes. Proc Natl Acad Sci USA 2005; 102: 449-454.
39. van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: Investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 1901-1928.
40. van der Burg M, Beverloo HB, Langerak AW, Wijsman J, van Drunen E, Slater R et al. Rapid and sensitive detection of all types of MLL gene translocations with a single FISH probe set. Leukemia 1999; 13: 2107-2113.
41. Andersson A, Höglund M, Johansson B, Lassen C, Billström R, Garwicz S et al. Paired multiplex reverse-transcriptase polymerase chain reaction (PMRT-PCR) analysis as a rapid and accurate diagnostic tool for the detection of MLL fusion genes in hematologic malignancies. Leukemia 2001; 15: 1293-1300.
42. van der Burg M, Poulsen TS, Hunger SP, Beverloo HB, Smit EM, Vang-Nielsen K et al. Split-signal FISH for detection of chromosome aberrations in acute lymphoblastic leukemia. Leukemia 2004; 18: 895-908.
43. Raffini LJ, Slater DJ, Rappaport EF, Nigro LL, Cheung NK, Biegel JA et al. Panhandle and reverse-panhandle PCR enable cloning of der(11) and der(other) genomic breakpoint junctions of MLL translocations and identify complex translocation of MLL, AF-4, and CDK6. Proc Natl Acad Sci USA 2002; 99: 4568-4573.
44. Harrison CJ, Cuneo A, Clark R, Johansson B, Lafage-Pochitaloff M, Mugneret F et al. Ten novel 11q23 chromosomal partner sites. European 11q23 Workshop participants. Leukemia 1998; 12: 811-822.
45. Meyer C, Burmeister T, Strehl S, Schneider B, Hubert D, Zach O et al. Spliced MLL fusions: A novel mechanism to generate functional chimaeric MLL · MLLT1 transcripts in t(11;19) (q23;p13.3) leukaemia. Leukemia 2007; 21: 588-590.
46. Hunger SP, Galili N, Carroll AJ, Crist WM, Link MP, Cleary ML. The t(1;19)(q23;p13) results in consistent fusion of E2A and PBX1 coding sequences in acute lymphoblastic leukemias. Blood 1991; 77: 687-693.
47. Kamps MP, Look AT, Baltimore D. The human t(1;19) translocation in pre-B ALL produces multiple nuclear E2A-Pbx1 fusion proteins with differing transforming potentials. Genes Dev 1991; 5: 358-368.
48. Wang GG, Pasillas MP, Kamps MP. Persistent transactivation by meis1 replaces hox function in myeloid leukemogenesis models: Evidence for co-occupancy of meis1-pbx and hox-pbx complexes on promoters of leukemia-associated genes. Mol Cell Biol 2006; 26: 3902-3916.
49. Cho JY, Akbarali Y, Zerbini LF, Gu X, Boltax J, Wang Y et al. Isoforms of the Ets transcription factor NERF/ELF-2 physically interact with AML1 and mediate opposing effects on AML1-mediated transcription of the B cell-specific blk gene. J Biol Chem 2004; 279: 19512-19522.
50. Wildonger J, Mann RS. The t(8;21) translocation converts AML1 into a constitutive transcriptional repressor. Development 2005; 132 2263-2272.
51. Kordes U, Krappmann D, Heissmeyer V, Ludwig WD, Scheidereit C. Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia 2000; 14: 399-402.
52. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001; 98: 2301-2307.